Association of serum angiopoietin-like protein 2 with carotid intima-media thickness in subjects with type 2 diabetes

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Jung, Chang Hee ^a   Lee, Woo Je ^a   Lee, Min Jung ^a   Kang, Yu Mi ^a   Jang, Jung Eun ^a   Leem, Jaechan ^a   La Lee, Yoo ^a   Seol, So Mi ^a   Yoon, Hae Kyeong ^a   Park, Joong Yeol ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Angiopoietin like protein 2; Atherosclerosis; Carotid; Intima media thickness; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANGIOPOIETIN 2; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; URIC ACID; ANGIOPOIETIN; ANGPTL2 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; AGED; ATHEROSCLEROSIS; BLOOD; DIABETES MELLITUS, TYPE 2; RISK FACTOR;

ADULT; AGED; ANGIOPOIETINS; ATHEROSCLEROSIS; BIOMARKERS; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84928037374     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0198-z     Document Type: Article

References (40)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.
2. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-8.
3. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. 2008;18(1):6-14.
4. Kadomatsu T, Endo M, Miyata K, Oike Y. Diverse roles of ANGPTL2 in physiology and pathophysiology. Trends Endocrinol Metab. 2014;25(5):245-54.
5. Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J. 2011;278(4):559-64.
6. Kim I, Moon SO, Koh KN, Kim H, Uhm CS, Kwak HJ, et al. Molecular cloning, expression, and characterization of angiopoietin-related protein. angiopoietin-related protein induces endothelial cell sprouting. J Biol Chem. 1999;274(37):26523-8.
7. Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol. 2014;5:4.
8. Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C, et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature. 2012;485(7400):656-60.
9. Horio E, Kadomatsu T, Miyata K, Arai Y, Hosokawa K, Doi Y, et al. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Arterioscler Thromb Vasc Biol. 2014;34(4):790-800.
10. Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009;10(3):178-88.
11. Thorin-Trescases N, Thorin E. Angiopoietin-like-2: a multifaceted protein with physiological and pathophysiological properties. Expert Rev Mol Med. 2014;16:e17.
12. Tian Z, Miyata K, Tazume H, Sakaguchi H, Kadomatsu T, Horio E, et al. Perivascular adipose tissue-secreted angiopoietin-like protein 2 (Angptl2) accelerates neointimal hyperplasia after endovascular injury. J Mol Cell Cardiol. 2013;57:1-12.
13. Tazume H, Miyata K, Tian Z, Endo M, Horiguchi H, Takahashi O, et al. Macrophage-derived angiopoietin-like protein 2 accelerates development of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2012;32(6):1400-9.
14. Farhat N, Thorin-Trescases N, Mamarbachi M, Villeneuve L, Yu C, Martel C, et al. Angiopoietin-like 2 promotes atherogenesis in mice. J Am Heart Assoc. 2013;2(3):e000201.
15. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14-22.
16. Jung CH, Lee MJ, Kang YM, Jang JE, Leem J, Lee YL, et al. Association of serum C1q/TNF-related protein-9 concentration with arterial stiffness in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(12):E2477-84.
17. Okita K, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, et al. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. Endocr J. 2013;60(3):283-90.
18. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;22(5):818-22.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70.
20. Yugar-Toledo JC, Bonalume Tacito LH, Ferreira-Melo SE, Sousa W, Consolin-Colombo F, Irigoyen MC, et al. Low-renin (volume dependent) mild-hypertensive patients have impaired flow-mediated and glyceryl-trinitrate stimulated vascular reactivity. Circ J. 2005;69(11):1380-5.
21. Lonn E. Use of carotid ultrasound to stratify risk. Can J Cardiol. 2001;17 Suppl A:22A-5.
22. Nelson MR, Stepanek J, Cevette M, Covalciuc M, Hurst RT, Tajik AJ. Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc. 2010;85(5):460-72.
23. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Gomez-Acebo I, Testa A, Garcia-Porrua C, et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm. 2012;2012:674265.
24. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J. 2011;35(6):561-6.
25. Usui T, Ninomiya T, Nagata M, Takahashi O, Doi Y, Hata J, et al. Angiopoietin-like protein 2 is associated with chronic kidney disease in a general Japanese population: the Hisayama Study. Circ J. 2013;77(9):2311-7.
26. Meng QX, Wen L, Chen XY, Zhong HJ. Association of serum angiopoietin-like protein 2 and epinephrine levels in metabolically healthy but obese individuals: and evidence. Exp Ther Med. 2013;5(6):1631-6.
27. Li Q, Gong W, Yang Z, Lu B, Yang Y, Zhao W, et al. Serum Angptl2 levels are independently associated with albuminuria in type 2 diabetes. Diabetes Res Clin Pract. 2013;100(3):385-90.
28. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(6):998-1005.
29. Oike Y, Tabata M. Angiopoietin-like proteins-potential therapeutic targets for metabolic syndrome and cardiovascular disease. Circ J. 2009;73(12):2192-7.
30. Kitazawa M, Nagano M, Masumoto KH, Shigeyoshi Y, Natsume T, Hashimoto S. Angiopoietin-like 2, a circadian gene, improves type 2 diabetes through potentiation of insulin sensitivity in mice adipocytes. Endocrinology. 2011;152(7):2558-67.
31. Doi Y, Ninomiya T, Hirakawa Y, Takahashi O, Mukai N, Hata J, et al. Angiopoietin-like protein 2 and risk of type 2 diabetes in a general Japanese population: the Hisayama study. Diabetes Care. 2013;36(1):98-100.
32. Ota T. Chemokine systems link obesity to insulin resistance. Diabetes Metab J. 2013;37(3):165-72.
33. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999;22(12):1971-7.
34. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131-5.
35. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875-80.
36. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 2005;69(1):29-35.
37. Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol. 2006;101(8):1824-33.
38. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol. 2005;46(6):1112-3.
39. Muramoto A, Tsushita K, Kato A, Ozaki N, Tabata M, Endo M, et al. Angiopoietin-like protein 2 sensitively responds to weight reduction induced by lifestyle intervention on overweight Japanese men. Nutr Diabetes. 2011;1:e20.
40. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-71.